Canopy Growth Shares Rise 2.44% to $1.26
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 13 2026
0mins
Moderately bullish activity in Canopy Growth (CGC), with shares up 3c, or 2.44%, near $1.26. Options volume relatively light with 9982 contracts traded and calls leading puts for a put/call ratio of 0.09, compared to a typical level near 0.2. Implied volatility (IV30) is up nearly 41.0 points near 173.88, in the highest 10% of observations over the past year, suggesting an expected daily move of $0.14. Put-call skew steepened, indicating increased demand for downside protection.
Analyst Views on CGC
Wall Street analysts forecast CGC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CGC is 3.78 USD with a low forecast of 1.80 USD and a high forecast of 5.76 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 1.190
Low
1.80
Averages
3.78
High
5.76
Current: 1.190
Low
1.80
Averages
3.78
High
5.76
About CGC
Canopy Growth Corporation is a Canada-based cannabis company. The principal activities of the Company are the production, distribution and sale of a diverse range of cannabis and cannabinoid-based products for both adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company delivers innovative products from owned and licensed brands, including Tweed, 7ACRES, DOJA, Deep Space, and Claybourne, as well as category defining vaporization devices by Storz & Bickel. Its segments include Canada cannabis, and Storz & Bickel. Its Canada cannabis segment includes the production, distribution, and sale of a range of cannabis, hemp, and cannabis related products in Canada. Its Storz & Bickel segment includes the production, distribution, and sale of vaporizers. In addition, it serves medical cannabis patients globally with principal operations in Canada, Europe and Australia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
